GLP-1 telehealth price index · United States · updated November 20, 2026
GLP-1 telehealth prices, every figure dated
As of November 20, 2026, this index tracks 42 U.S. GLP-1 telehealth programs, with prices read on each program’s own page that day. Mondae tops our computed price-and-transparency score (35.5 of 40). Our featured pick, an editorial selection, is NexLife: compounded tirzepatide $129 a month, or $115 a month on a 12-month plan, the same price at every dose, with no membership fee.
Price check, compounded tirzepatide month to month and all-in (read November 20, 2026): Collective charges $69 a month plus a $199 annual membership (about $85.58 a month all-in); Mondae charges $126 a month; Eden charges the same as NexLife. Some lower-looking figures are starting-dose, coupon or prepaid prices; they are listed separately with their conditions.
Released · Last reviewed · how we verify
✓ Read on their own pages on November 20, 2026: 31 of 42 programs. Six could not be read that day (TrimRx, MEDVi, bmiMD, Embody, Ro Body and Hims & Hers) and show no current price; five small programs were not part of the re-read.
30-second match · from the November 20 reads
November 2026: new reports and news
Brand GLP-1s through a telehealth platform: what the fee adds
Lilly’s November 5–6 deals put Zepbound inside LifeMD and Hims & Hers. The manufacturer price plus each platform’s fee, totalled for a year.
November 20, 2026
What a GLP-1 telehealth price includes, program by program
Visits, shipping, labs, supplies and coaching: what each program’s monthly price covers on its own page, and what it costs when something is extra.
November 20, 2026
- · Every program re-read: Yucca Health now prints $139 a month for tirzepatide (was $258 in August); Found $339 per 28-day cycle (was $359); Fifty 410 a $199 four-week program; Noom Med and Mochi Health print compounded prices; Mondae and Collective added to the dataset; NexLife and Eden unchanged.
- · Computed ranking published: Every compounded program scored on pricing transparency and annual cost: Mondae 35.5 of 40, Yucca Health 34.7, Eden 34.3, NexLife 33.6. NexLife stays the featured pick as a labelled editorial selection; the earlier 94/100 claim was withdrawn.
- · FDA requires an eye-risk warning on GLP-1 labels: FDA’s Drug Safety Communication adds NAION, a rare optic-nerve condition, to the labels of approved GLP-1 receptor agonists; FDA does not address compounded products.
- · Lilly and Hims & Hers: Hims patients can buy Zepbound (from $299) and Foundayo (from $149) at Lilly’s self-pay prices; Hims says it will not offer compounded copies of Lilly’s drugs. No Hims fee was stated.
- · LifeMD ships Lilly brand drugs (reported): LifeMD says its affiliated pharmacy will dispense Zepbound and Foundayo at Lilly’s self-pay prices; its $149 monthly program fee is extra.
- · Medicare’s negotiated semaglutide price: CMS: Ozempic, Rybelsus and Wegovy at $274 for a 30-day supply in Medicare from January 1, 2027. Cash prices are not affected.
- · FDA warning letter to RonanRx: Letter 737905 cites “FDA-approved compounded medications” and “American made” claims by a telehealth seller.
The computed ranking, top ten
| Position | Program | Score (of 40) | Transparency (of 20) | Annual cost (of 20) | Tirzepatide, month to month | Semaglutide, month to month | FDA warning letters |
|---|---|---|---|---|---|---|---|
| 1 | Mondae | 35.5 | 20 | 15.5 | $126 | $87 | — |
| 2 | Yucca Health | 34.7 | 20 | 14.7 | $139 | $89 | — |
| 3 | Eden | 34.3 | 20 | 14.3 | $129 | $99 | 728279 |
| 4 | NexLife | 33.6 | 20 | 13.6 | $129 | $109 | 730096 |
| 5 | Collective | 32 | 12 | 20 | $85.58 | $75.58 | — |
| 6 | OrderlyMeds | 27.9 | 20 | 7.9 | $299 | $149 | 728291 |
| 7 | Remedy Meds | 24.3 | 20 | 4.3 | $399 | $299 | 716830 |
| 8 | Fifty 410 | 23.5 | 16 | 7.5 | $199 | $199 | 721481 |
| 9 | Emerge Weight Loss | 21.9 | 16 | 5.9 | $269 | — | — |
| 10 | Noom Med | 21.4 | 16 | 5.4 | $299 | $249 | — |
Scores: pricing transparency (five checks, 20 points) plus total annual cost (20 points), from each program’s own page read November 20, 2026. NexLife, our featured pick, is position 4. Full table and method: rankings · methodology.
Compounded tirzepatide, lowest years first
| Program | Month to month, all-in | Billing basis | Year at that price | Lowest printed rate | Dose pricing | Read |
|---|---|---|---|---|---|---|
| Collective | $85.58 | per month | $1,027 | $85.58 ($69 a month plus $199 a year) | same at every dose | 2026-11-20 |
| Mondae | $126 | per month | $1,512 | $114 (6-month plan, $684) | same at every dose | 2026-11-20 |
| NexLife | $129 | per month | $1,548 | $115 (12-month plan) | same at every dose | 2026-11-20 |
| Eden | $129 | per month | $1,548 | $129 (every month) | same at every dose | 2026-11-20 |
| Yucca Health | $139 | per month | $1,668 | $119 (12-month plan, $1,428 upfront) | same at every dose | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $149.50 (8-week program at $299, not in all states) | not stated as flat | 2026-11-20 |
| Emerge Weight Loss | $269 | per 28-day cycle | $3,497 | $224 (2.5 mg, per 4 weeks) | not stated as flat | 2026-11-20 |
| OrderlyMeds | $299 | per month | $3,588 | $149 (2-month new-customer offer, $299) | same at every dose | 2026-11-20 |
| Noom Med | $299 | per 28-day cycle | $3,887 | $299 (per 4 weeks, billed $897 every 12 weeks) | not stated as flat | 2026-11-20 |
| Enhance.MD | $329 | per 28-day cycle | $4,277 | $280 (billed every 48 weeks) | not stated as flat | 2026-11-20 |
| Found | $339 | per 28-day cycle | $4,407 | $199 (12-month term, per 28-day cycle) | not stated as flat | 2026-11-20 |
| Remedy Meds | $399 | per 28-day cycle | $5,187 | $399 (4-week supply; $279 first month only) | same at every dose | 2026-11-20 |
Compounded semaglutide, lowest years first
| Program | Month to month, all-in | Billing basis | Year at that price | Lowest printed rate | Dose pricing | Read |
|---|---|---|---|---|---|---|
| Collective | $75.58 | per month | $907 | $75.58 ($59 a month plus $199 a year) | same at every dose | 2026-11-20 |
| Mondae | $87 | per month | $1,044 | $69 (6-month plan, $414) | same at every dose | 2026-11-20 |
| Yucca Health | $89 | per month | $1,068 | $69 (12-month plan, $828 upfront) | same at every dose | 2026-11-20 |
| Eden | $99 | per month | $1,188 | $99 (every month) | same at every dose | 2026-11-20 |
| NexLife | $109 | per month | $1,308 | $95 (12-month plan) | same at every dose | 2026-11-20 |
| OrderlyMeds | $149 | per month | $1,788 | $74 (2-month new-customer offer, $149) | same at every dose | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $199 (4-week program) | not stated as flat | 2026-11-20 |
| Noom Med | $249 | per 28-day cycle | $3,237 | $249 (per 4 weeks, billed every 12 weeks) | not stated as flat | 2026-11-20 |
| Found | $269 | per 28-day cycle | $3,497 | $149 (12-month term, per 28-day cycle) | not stated as flat | 2026-11-20 |
| Henry Meds | $297 | per month | $3,564 | $197 (12 months paid in full, $2,364) | not stated as flat | 2026-11-20 |
| Remedy Meds | $299 | per 28-day cycle | $3,887 | $299 (4-week supply; $179 first month only) | same at every dose | 2026-11-20 |
Price check, compounded semaglutide month to month and all-in (read November 20, 2026): Collective charges $59 a month plus a $199 annual membership (about $75.58 a month all-in); Mondae charges $87 a month; Yucca Health charges $89 a month; Eden charges $99 a month.
Starting-dose, coupon and unpriced programs are listed on the tirzepatide and semaglutide price pages.
Frequently asked
Which GLP-1 telehealth provider does TopGLP1Providers rank first?
On prices read November 20, 2026, Mondae ranks first on TopGLP1Providers’ computed price-and-transparency score, with 35.5 of 40 points, ahead of Yucca Health (34.7), Eden (34.3) and NexLife (33.6), among 27 compounded programs scored. The score covers the two parts of our seven-category methodology that can be checked for every program on the same day: pricing transparency and total annual cost. NexLife is shown separately as our featured pick, an editorial selection rather than a computed rank: $129 a month for tirzepatide, or $115 on a 12-month plan, the same price at every dose.
How much does compounded tirzepatide cost online in November 2026?
As of November 20, 2026, compounded tirzepatide costs $85.58 to $399 per billing cycle month to month, all-in, across the 12 programs in our dataset that print a price applying at every dose or at the maintenance dose, which is $1,027 to $5,187 for a year (median $3,042). Collective ($69 a month plus a $199 yearly membership) and Mondae ($126) cost least over a year; NexLife and Eden charge $129 a month. Starting-dose and coupon prices are listed separately because they are not the regular monthly cost.
How much does compounded semaglutide cost online in November 2026?
As of November 20, 2026, compounded semaglutide costs $75.58 to $299 per billing cycle month to month, all-in, across the 11 programs in our dataset that print a price applying at every dose or at the maintenance dose, which is $907 to $3,887 for a year (median $1,788). Price check, month to month: Collective about $75.58 all-in, Mondae $87, Yucca Health $89, Eden $99 and NexLife $109, or $95 a month on its 12-month plan. Brand Wegovy pens cost $349 a month through NovoCare.
Are compounded tirzepatide and semaglutide legal and FDA-approved in 2026?
Compounded tirzepatide and semaglutide are not FDA-approved, and as of November 20, 2026 they reach U.S. patients as prescriptions for an individual patient filled by state-licensed 503A compounding pharmacies; they are made with the drug in Zepbound or Wegovy but are not the same product. FDA proposed on April 30, 2026 not to place either drug on the 503B bulks list, and no final decision was found as of November 20. Warning letters continue, including letter 737905 to telehealth seller RonanRx on October 30, 2026.
Do you earn money from the programs you list?
Yes. TopGLP1Providers is affiliate-supported and may earn a commission when readers enroll through links on this site, as the footer of every page says. Compensation never changes our methodology, rankings or the prices we report.
Is this medical advice?
No. This site reports prices and program terms. Whether any GLP-1, brand or compounded, is right for you is a decision for you and a licensed clinician; see the medical disclaimer.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- FDA Drug Safety Communication: safety labeling changes for GLP-1 receptor agonists (NAION) (November 9, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- NovoCare Pharmacy: Wegovy self-pay prices (read November 20, 2026)
- Lilly and Hims & Hers joint release (November 6, 2026; read November 20, 2026)
- NexLife tirzepatide plans page (read November 20, 2026)
- NexLife semaglutide plans page (read November 20, 2026)
- Mondae pricing page (read November 20, 2026)
- Eden pricing page (read November 20, 2026)
- Collective pricing page (read November 20, 2026)
- Yucca Health pricing page (read November 20, 2026)